Status Plus

abstract

abstract

316

Low intensity shock wave tissue coverage for management of Erectile Dysfunction patients: preliminary comparative study

Abou Taleb, A1; El-Shaer, W1; kandeel, W1; dakhakhny, A1; el nahif, E1; Abd Elbaky, A1

1: Benha university, Egypt

Purpose: Is to evaluate the efficacy and safety of low intensity shockwave tissue coverage (LSTC) on management of impotent patients non- phosphodiesterase-5 inhibitors (PD5-I) responders.

Patient and Methods: In, All 84 patients were included in the study from May 2015 to August 2017. They were divided into two groups; sever and non-sever. All patients fulfilled the inclusion criteria which were ED more than 6 months of organic cause, failed PD5-I and had a score ≤ 21 on SHIM and at least 1 month of PD5-I abstinence. Patients were excluded if they underwent radical prostatectomy, pelvic radiotherapy, and patient of ED of hormonal or psychogenic causes. Piezowave2 (Richard Wolf GmbH) was employed. Treatment protocol was once weekly of 4000 shocks of LSTC distributed on both corpora cavernousa and perineum for four weeks to reach 16000 shock waves. All patients were evaluated at base line and at 3, 6,9,12 months post.

Results: SHIM score and Treatment Satisfaction Questionnaire (TSQ) were used for evaluation of outcome. There was improvement in SHIM score of both groups as baseline score was 12.5 ± 4.4 and changed to 17 ± 5.3, 17.4 ±5.8, 17.1±5.8 and 16.1± 5.7 at 3, 6, 9 and 12 months post treatment in non-severe group (p<0.001). while in severe group it was 4.5±2.3, 6.8± 3.8, 6.7±4, 6.5±3.8, 5.7±3.5 at baseline, 3, 6, 9, 12 months post treatment respectively (p<0.001). In non-severe group; 71% of patients were satisfied and 73% were improved. while in the severe group 9.3% were satisfied and 4.7% of patients felt improvement after treatment, in both groups; no patient had pain nor other side effects during or after treatment.

Conclusion: LSTC-ED is safe associated with excellent results especially in non-severe ED patients, and in small cohort of patients with severe ED especially who are candidate for prosthesis. But the durability of this line of management is questionable.

Disclosure:

Work supported by industry: no.

Go Back